|
مقاله
|
Abstract
|
|
|
|
Title:
|
Efficacy of intravitreal bevacizumab monotherapy in retinopathy of prematurity
|
|
Author(s):
|
Nasser Shoeibi MD, SeyedehMaryam Hosseini MD, Majid Abrishami MD , Mirnaghi Moosavi MD ,Touka Banaee MD ,Zahra Bakhshi Golestani MD
|
|
Presentation Type:
|
Oral
|
|
Subject:
|
Posterior Segment and Uveitis
|
|
Others:
|
|
|
Presenting Author:
|
|
|
Name:
|
Seyedeh Maryam Hosseini
|
|
Affiliation :(optional)
|
Eye Research Center ,Retina research center ,Khatam Hospital ,Mashhad University of Medical Sciences
|
|
E mail:
|
smaryam_hosseini@yahoo.com
|
|
Phone:
|
05137281401
|
|
Mobile:
|
09153172911
|
|
|
|
|
Purpose:
|
This study aims to evaluate the efficacy of off-label use of intravitreal bevacizumab (IVB) monotherapy in retinopathy of prematurity(ROP).
|
|
Methods:
|
This single center retrospective, non-comparative case series study included all infants who consecutively underwent intravitreal IVB injection as monotherapy for stage 3 (plus disease) of ROP in Khatam-al-Anbia Eye Hospital at Mashhad University of Medical Science. Medical records of 89 infants from October 2011 throughout March 2015 were reviewed. We recorded demographic data and ocular findings at the beginning and follow up visits.
|
|
Results:
|
This study includes 157 eyes of 89 infants and 168 injection of which 86 (51.2%) had zone 1 disease and 82 (48.8%) had zone 2 disease. 11 eyes (7%) received second injection. Mean Birth weight and gestational age were 1154±265 gr and 28.6±1.5 w respectively. Mean time of Plus disease resolution and start of vascularization was 17.6±22.5 and 44.4±44.4 day after injection respectively. Mean post menstrual age of last follow up was 66.7±14.2 w. No patient showed ocular or short term systemic side effects.
|
|
Conclusion:
|
Intravitreal Bevacizumab monotherapy is an effective and safe treatment modality in patients with stage 3 retinopathy of prematurity.
|
|
Attachment:
|
|
|
|